Pancreatic Cancer Research

ResearcherThe University of Texas at San Antonio Health Science CenterActive in the last 2 years

Devalingam Mahalingam

ORCID-verified (high confidence, 0.95), identity_conf@1As of 6 November 2026

Matched on ORCID iD 0000-0002-2979-9894; OpenAlex author ID A5004814161. Sources: ClinicalTrials.gov.

Their work

Papers
9 (first author 1, last author 2)
Trials
4 (principal investigator on 4)
Grants
0
Labs led
1
Collaborators
30
Papers, trials and grants by year

2015: 1 paper · 2016: none · 2017: none · 2018: 2 papers, 1 trial · 2019: none · 2020: 1 paper · 2021: none · 2022: 1 trial · 2023: 1 paper, 1 trial · 2024: none · 2025: 2 papers · 2026: 2 papers, 1 trial

Papers 9

  1. Elraglusib and chemotherapy in metastatic pancreatic ductal adenocarcinoma: a randomized controlled phase 2 trial. Co-author DOI 10.1038/s41591-026-04327-4↗
  2. KRAS Subtype Modifies Outcomes with Immunomodulatory Therapy in Advanced Pancreatic Ductal Adenocarcinoma: Evidence from Early-Phase Trials. Last author DOI 10.3390/cancers18132037↗
  3. Phase II study of elraglusib (9-ING-41), a GSK-3β inhibitor, in combination with gemcitabine plus nab-paclitaxel in previously untreated metastatic pancreatic … Co-author DOI 10.1016/j.esmoop.2025.105122↗
  4. Threading the Needle: Navigating Novel Immunotherapeutics in Pancreatic Ductal Adenocarcinoma. Last author DOI 10.3390/cancers17050715↗
  5. Combination of pembrolizumab and pelareorep promotes anti-tumour immunity in advanced pancreatic adenocarcinoma (PDAC). Co-author DOI 10.1038/s41416-023-02344-5↗
  6. Pembrolizumab in Combination with the Oncolytic Virus Pelareorep and Chemotherapy in Patients with Advanced Pancreatic Adenocarcinoma: A Phase Ib Study. Co-author DOI 10.1158/1078-0432.ccr-19-2078↗
  7. Immunotherapy in pancreatic adenocarcinoma-overcoming barriers to response. First author DOI 10.21037/jgo.2018.01.13↗
  8. A Phase II Study of Pelareorep (REOLYSIN®) in Combination with Gemcitabine for Patients with Advanced Pancreatic Adenocarcinoma. Co-author DOI 10.3390/cancers10060160↗
  9. The combination of intravenous Reolysin and gemcitabine induces reovirus replication and endoplasmic reticular stress in a patient with KRAS-activated pancreat… Co-author DOI 10.1186/s12885-015-1518-0↗

Trials 4

  1. BMS-986504 in Combination With Pemetrexed for the Treatment of Metastatic Solid Tumors With MTAP Deletion Principal investigator NCT07594626↗
  2. CPI-613 (Devimistat) in Combination With Hydroxychloroquine and 5-fluorouracil or Gemcitabine in Treating Patients With Advanced Chemorefractory Solid Tumors Principal investigator NCT05733000↗
  3. Study of Sotorasib Combined With Chemotherapy for Second Line Treatment of Pancreas Cancer Principal investigator NCT05251038↗
  4. Pembrolizumab and Pelareorep in Treating Patients With Advanced Pancreatic Cancer Principal investigator NCT03723915↗

Closest collaborators

The 25 strongest of 30 by collab_strength@1: shared papers, trials and grants, recent and small-team work weighing most.

  1. Mary F. Mulcahy · 4 shared papers, 2023–2026 · strength 0.86
  2. Tarık Demir · 2 shared papers, 2025–2026 · strength 0.71
  3. Sheetal Mehta Kircher · 2 shared papers, 2023–2026 · strength 0.45
  4. Aparna Kalyan · 2 shared papers, 2023–2026 · strength 0.45
  5. Al B. Benson · 2 shared papers, 2023–2026 · strength 0.45
  6. Benedito A. Carneiro · 2 shared papers, 2025–2026 · strength 0.41
  7. Andrès M.R. Cervantes · 2 shared papers, 2025–2026 · strength 0.41
  8. Andrew L. Coveler · 2 shared papers, 2025–2026 · strength 0.41
  9. Vaibhav Sahai · 2 shared papers, 2025–2026 · strength 0.41
  10. Dılşa Mızrak Kaya · 1 shared paper, 2026 · strength 0.29
  11. Bin Zhang · 2 shared papers, 2020–2023 · strength 0.26
  12. Rachna T. Shroff · 1 shared paper, 2026 · strength 0.22
  13. Noelle K. LoConte · 1 shared paper, 2026 · strength 0.22
  14. Anne Ploquin · 1 shared paper, 2026 · strength 0.22
  15. Petr Kavan · 1 shared paper, 2026 · strength 0.22
  16. Ryan Michael Carr · 1 shared paper, 2026 · strength 0.22
  17. Tanios Bekaii‐Saab · 1 shared paper, 2026 · strength 0.22
  18. Simon Pernot · 1 shared paper, 2026 · strength 0.22
  19. Charles D. Lopez · 1 shared paper, 2026 · strength 0.22
  20. Alexander Grenander Raufi · 1 shared paper, 2025 · strength 0.19
  21. Steven Francis Powell · 1 shared paper, 2025 · strength 0.19
  22. Marisol Huerta · 1 shared paper, 2025 · strength 0.19
  23. Ludimila L. Cavalcante · 1 shared paper, 2025 · strength 0.19
  24. Anwaar Saeed · 1 shared paper, 2025 · strength 0.19
  25. Jordan D. Berlin · 1 shared paper, 2025 · strength 0.19

How to reach this person

A chain of introductions through people who have published, run trials or held grants together (warm_path@1: fewest links first, then the strongest). Built from public records only; no contact details are kept.